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Abstract
We describe the first outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP), the infection control
measures adopted and the shift in resistance patterns of isolates during antibiotic treatment. The ST258 KPC-KP strain exhibited a
multiresistant antibiotic phenotype including co-resistance to gentamycin, colistin and tigecycline intermediate susceptibility. Isolates
before and after treatment had different behaviour concerning their antibiotic susceptibility and the population analysis profile study. A
progressive increase in the aminoglycosides (acquiring amicacin resistance) and b-lactam MICs, and a decreased susceptibility to
fosfomycin was observed throughout the administration of combined antimicrobial regimens including meropenem. A high meropenem
resistance KPC-KP homogeneous population (MIC 256 Jg/mL), could arise from the meropenem heterogeneous low-level resistance
KPC-KP population (MIC 8 Jg/mL), by the selective pressure of the prolonged meropenem therapy. The kpc gene was inserted in a
Tn4401 isoform a, and no transconjugants were detected. The core measures adopted were successful to prevent evolution towards
resistance dissemination.
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Introduction
Carbapenems are recommended for severe infections caused
by extended spectrum b-lactamase (ESBL) -producing Entero-
bacteria, because of their resistance to third-generation
cephalosporins and associated resistance to almost all other
antibiotics. Therefore the emergence of carbapenem-resis-
tance in Enterobacteria is worrying, and could be related to
several combined mechanisms involving outer membrane
permeability defects, hyperproduction of AmpC cephalospo-
rinases, ESBL and carbapenemase production [1].
Klebsiella pneumoniae carbapenemases (KPC) are the most
frequent carbapenemases found in Klebsiella pneumoniae and
are mostly plasmid encoded, but chromosomal location has
also been reported [2]. As the gene encoding KPC usually
resides on transferable plasmids, it is capable of disseminating
to other Gram-negative genera [3]. The worldwide spread of
KPC-producing K. pneumoniae strains (KPC-KP) has revealed
the successful dissemination of a major clone defined as
sequence type 258 (ST258). Since 2006, KPC-KP has arisen in
South America, particularly in countries bordering Uruguay—
Argentina and Brazil [4,5].
A high frequency of ESBL-producing K. pneumoniae isolates
(70%) has been reported in intensive care unit (ICU) patients
but no cases of KPC-producing isolates had been reported in
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the country up to April 2011 [6]. We describe the first two
clinical cases of KPC-KP infections in Uruguay, their pheno-
typic and genotypic characteristics, the shift of resistance
patterns during antibiotic treatment and the infection control
measures adopted.
Methods
Hospital setting characteristics
The ‘Sanatorio Mautone’ is a 65-bed acute general hospital
located in Maldonado-Punta del Este, a tourist area receiving
500 000 tourists annually from Argentina, Brazil and to a lesser
extent from the USA and Europe. The ICU has six beds, one in
an isolation room and the others in a common area separated
by curtains.
Clinical cases
Patient A. On 20 February 2011 a 30-year-old man (Table 1)
was admitted from home to the ICU for severe enteric sepsis
caused by a Salmonella sp. that was nalidixic acid and
ciprofloxacin susceptible, recovered from blood and stool
cultures. He was mechanically ventilated due to septic shock
and acute respiratory distress syndrome and intravenous
ciprofloxacin treatment was started. This patient had Evans
syndrome associated with systemic lupus erythematosus
treated with corticosteroids and immunosuppressants. He
had never required medical care in any other country. He first
developed an Escherichia coli tracheobronchitis treated with
piperacillin-tazobactam, and later developed a Pseudomonas
aeruginosa ventilator-associated pneumonia with secondary
bacteraemia that was treated with imipenem for 13 days. On
26 March a urine specimen grew P. aeruginosa and KPC-KP
(A1). A second urine specimen grew KPC-KP (A2) as well.
This catheter-related asymptomatic bacteriuria was not
treated. On 31 March the patient developed fever and septic
shock and blood cultures grew Salmonella sp. susceptible to
nalidixic acid, ciprofloxacin and imipenem, treated with
ciprofloxacin and imipenem; he progressed to refractory
septic shock and died on 7 April. On 6 April the central venous
catheter tip grew 10 CFU of KPC-KP (A3) and the blood
cultures were negative.
Patient B. On 15 March 2011 a 67-year-old man (Table 1) with
severe chest trauma was hospitalized in ICU with respiratory
failure requiring mechanical ventilation. Piperacillin-tazobactam
treatment was started for suspected pulmonary infection. The
patient was diabetic with a history of chronic hypertension. He
had not required medical care in any other country. On 20
March the patient developed a P. aeruginosa ventilator-associ-
ated pneumonia with secondary bacteraemia treated with
imipenem for 9 days and then with piperacillin-tazobactam and
ciprofloxacin. Patient condition improved and the orotracheal
tube was removed on 4 April. Three days later he developed
respiratory failure and mechanical ventilation was reinstalled.
On 7 April KPC-KP (B1) was recovered from respiratory
secretions and from the central venous catheter tip (100 CFU)
(B2). On 9 April the patient developed a ventilator-associated
pneumonia caused by KPC-KP (B3) with septic shock. Blood
cultures were negative, and cultures from urine and perianal
swabs grew KPC-KP (B4, B5). Initially a high dose of doxycy-
cline (200 mg every 6 h) plus rifampicin (600 mg every 24 h)
and meropenem (2 g in a 3-h infusion every 8 h) were started.
The patient’s condition improved and noradrenalin infusion was
TABLE 1. Characteristics of the patients, treatments and KPC-producing Klebsiella pneumoniae isolates
Diagnosis and antimicrobial treatment Date Isolate (Specimen) Synergy tests/blaKPC-2 Sequence type PFGE (XbaI)
Patient A SLE, Enteric Salmonella sepsis; CIP 20/02
Escherichia coli Tracheobronchitis; PTZ 27/02
Pseudomonas aeruginosa VAP with
secondary bacteraemia; IMP
10 al 23/03
P. aeruginosa persistent tracheal 26/03 A1 (Urine) +/nd nd nd
Samonella bacteraemia and Septic shock; IMP plus CIP 30/03
31/03
A2 (Urine) +/+ ST258 A
06/04 A3 (Catheter) +/nd nd nd
Patient B Chest trauma, respiratory failure, Diabetic; PTZ 15/03
P. aeruginosa VAP with secondary bacteraemia; IMP 20 al 30/03
P. aeruginosa persistent tracheal infection 1 al 09/04
Mechanical ventilation reinstalled 07/04 B1 (TA)
B2 (Catheter)
+/+
+/+
ST258
nd
A
A
KPC-KP VAP, Septic shock; DOX plus RIF plus MEM 09/04 B3 (TA)
B4 (Urine)
B5 (Rectal)
B6 (TA)
+/nd
+/nd
+/nd
+/+
nd
nd
nd
ST258
nd
nd
nd
A
TIG plus RIF plus MEM Respiratory failure,
P. aeruginosa bacteraemia
14/04
28/04
CIP, ciprofloxacin; PFGE, pulsed-field gel electrophoresis; PTZ, piperacillin-tazobactam; IPM, imipenem; DOX, doxycycline; RIF, rifampin; MEM, meropenem; TYG, tigecycline; A1,
>105 CFU/mL K. pneumoniae and P. aeruginosa; A2, >10
5 CFU/mL of K. pneumoniae; A3, 10 CFU of K. pneumoniae in the tip of central line catheter; B2, 100 CFU of K. pneumoniae;
B4, >10
5 CFU mL1 of K. pneumoniae; +, difference of ≥5 mm in zones between MEM and MEM plus boronic acid and <5 mm in zone between MEM and MEM plus cloxacillin and
MEM plus dipicolinic acid; nd, not determined; SLE, systemic lupus erythematosus; VAP, ventilator-associated pneumonia; TA, tracheal aspirate.
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stopped. On 14 April doxycycline was substituted by tigecycline
(100 mg every 12 h), which became available for the first time
in Uruguay. Antimicrobial treatment was stopped on 25 April.
On 28 April the respiratory failure persisted, respiratory
secretions were positive for KPC-KP (B6) and P. aeruginosa and
blood culture was positive for P. aeruginosa. Finally on 3 May
the patient died of refractory respiratory failure.
Infection prevention and control measures
The Infection Control Committee, considering the unusual
antimicrobial resistance phenotype of K. pneumoniae isolates
suspected nosocomial cross-transmission and decided to
implement control measures, perform an epidemiological
investigation and notify the public health authorities [7,8].
Control measures adopted were: meeting with hospital
(clinicians, nurses, laboratory, housekeeping) and administra-
tion staff; extended contact isolation precautions for ICU
patients with daily monitoring (isolation room and dedicated
staff for the colonized and the infected patients, exclusive
work clothes to use with these patients, strict hand hygiene
with alcohol gel, reinforcement of the unshared use of
instruments and disinfection between patients of shared
instruments); screening of patients in contact with colonized
or infected patients and pre-emptive isolation while await-
ing results; closing the ICU to new patients; and reinforce-
ment of environmental hygiene with alcohol or chlorinated
agents. The surveillance cultures for the identification of
KPC-KP intestinal-tract-colonized patients were performed
according to the CDC protocol [9]. Respiratory secretions
and urine were evaluated following conventional culture
methods.
Identification and antimicrobial susceptibility studies
The identification and the antibiotic susceptibility testing were
performed using the VITEK 2 C (bioMerieux, Marcy l’Etoile,
France) system. The MICs of imipenem, meropenem, tigecy-
cline, colistin and gentamycin were determined using E-test
(bioMerieux). CLSI clinical breakpoints were applied, except
for tigecycline and colistin where EUCAST (http://www.eucast.
org) breakpoints were used [10,11]. ESBL testing was
performed according to CLSI guidelines.
Susceptibility to fosfomycin was assayed by disc diffusion
[12]. KPC phenotype was determined by synergy test using
KPC/MBL confirm kit (ROSCO Diagnostica A/S, Denmark).
The population analysis profile was determined for merope-
nem as described elsewhere [13].
Molecular studies
Screening for resistance genes was performed by PCR,
following reported conditions for blaTEM, blaSHV, blaCTX-M,
blaKPC, blaIMP, blaVIM gene families, and blaPER-2, aacA4, qnrA and
qnrB genes [14–20].
The genetic environment of blaKPC-2 gene was studied by
PCR mapping with specific primers for ISKpn6 or ISKpn7 or
tnpA and blaKPC-2. PCR amplification of the complete ompK36
gene was performed [21].
Crude extracts were subjected to isoelectrofocusing with
the use of PhastSystem and PhastaGels IEF 3–9 (Pharmacia,
Stockholm, Sweden).
Genetic relatedness
The genetic relatedness of KPC-KP isolates was evaluated by
pulsed field gel electrophoresis using XbaI-digested total DNA
and interpreted by Tenover criteria [22]. Multilocus sequence
typing with seven housekeeping genes was performed accord-
ing to the protocol described on the K. pneumoniae multilocus
sequence typing website (http://www.pasteur.fr/mlst/Kpneu-
moniae.html).
Mating experiments
To determine whether the blaKPC-2 gene was on a transferable
element, isolates A1 and B1—cefotaxime resistant, rifampin
and sodium azide sensitive—were mated in three independent
assays with E. coli strain Top10—cefotaxime susceptible,
rifampin and sodium azide resistant. They were cultured for
18 h at 35°C, in M€uller–Hinton agar (MHA) containing
cefotaxime 2 mg/L or rifampin 200 mg/L. The growth was
suspended in MH broth (MHB) to achieve a 1 MacFarland
turbidity standard, and 0.5 mL of the mix of equal volumes of
the donor and receptor suspensions was plated as a drop in
the middle of an MHA plate, and incubated for 18 h at 35°C.
Serial decimal dilutions of the suspension in 1 mL MHB of the
total growth were prepared. Transconjugants were selected
from 101 and 102 dilutions in MHA containing cefotaxime
2 mg/L and rifampin 200 mg/L and confirmed by positive
growth in MHA containing sodium azide 100 lg/mL and
positive PCR for blaKPC-2 gene.
Results
The ICU remained closed to new admissions while KPC-KP-in-
fected patients were still hospitalized. Three patients were
considered contacts because they shared their stay in ICU with
KPC-KP-infected patients. Two of them were discharged with
negative surveillance cultures that persisted negative on days 15
and 30 thereafter. Surveillance cultures of the third contact
were performed every 48 h with negative results. The epide-
miological investigation identified a diabetic patient with a
history of contact with the healthcare system in New York,
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USA, who was admitted to the ICU 17 days before the first
isolation of KPC-KP. She had a severe urosepsis caused by
non-multiresistant E. coli and hadmultiple episodes of diarrhoea
during the 5 days of hospitalization. When the ICU was free of
patients, it underwent a thorough cleaning and environmental
disinfection. Five months later two colonized cases were
detected (asymptomatic urinary catheter bacteriuria and
hepatic drain of quistostomy), similar control measures were
applied, surveillance cultures were performed during the next
6 months and no more cases have been identified since then.
All K. pneumoniae isolates recovered showed a multiresis-
tant phenotype but were susceptible to fosfomycin, ESBL-neg-
ative and exhibited a KPC phenotype. Different values for
MICs to b-lactams and gentamycin were observed for the
isolates from patient B (Table 2). The fosfomycin inhibition
zone diameters were 22 and 17 mm for B1 and B6 isolates,
respectively. Scattered colonies were observed within the
inhibition zone of meropenem for A2 and B1 whereas B6
showed no inhibition zone.
The B1 isolate population analysis profile showed a
heterogeneous population with a subset of 0.01–0.001%
growing at meropenem concentrations ranging from 16 to
128 µg/mL. The B6 isolate population analysis profile showed
that >0.01% of cells grew up to 512 µg/mL.
The isolates A2, B1, B2 and B6 revealed the presence of a
blaKPC-2, blaTEM-1, blaSHV-1 and aacA4 genes. Isoelectrofocusing
showed that these isolates shared two common b-lactamase
activities with isoelectric points of 5.4 and 6.7, characteristic of
TEM-1 and KPC-2 enzymes, respectively. PCR mapping
revealed a 4-kb genetic region containing tnpA, ISKpn7,
blaKPC-2 and ISKpn6 genes, consistent with a Tn3-based
Tn4401 isoform a, since a 100-bp deletion was detected
upstream of the blaKPC-2 gene (Fig. 1) [23]. Sequence analysis
of ompK36 DNA revealed a 99% similarity with a described
gene encoding a functional OmpK36 porin (Accession number
FJ577673).
Biparental conjugation did not render transconjugants,
indicating a conjugation frequency less than 1 9 108/
recipient.
Discussion
In the present study we describe the first nosocomial outbreak
caused by KPC-KP in Uruguay. Considering that none of the
patients had a history of recent travel abroad, it is possible that
an unrecognized colonized patient with a history of admission
in a healthcare facility in one of the endemic areas introduced
TABLE 2. Susceptibility of KPC-producing Klebsiella pneumoniae isolates
K. pneumoniae isolate
Vitek MIC lg mL1 to: E-test MIC lg mL1 to:
TZP FOX CTX CAZ CEP GEM ANK CIP COL IPM MEM IPM MEM TYG COL
A1 ≥128/4 ≥64 16 16 8 ≥16 16 ≥4 ≥16 8 4 8 4 2 24
A2 ≥128/4 ≥64 16 16 8 ≥16 16 ≥4 ≥16 8 4 8 4 2 24
B1 ≥128/4 ≥64 16 16 8 ≥16a 32 ≥4 ≥16 ≥16 4 8 8 2 24
B2 ≥128/4 ≥64 16 16 8 ≥16 32 ≥4 ≥16 ≥16 4 8 8 2 24
B3 ≥128/4 ≥64 16 16 8 ≥16 32 ≥4 ≥16 ≥16 4 8 8 2 24
B5 ≥128/4 ≥64 16 32 8 ≥16 32 ≥4 ≥16 ≥16 8 16 8 2 24
B6 ≥128/4 ≥64 ≥64 ≥64 ≥64 ≥16b ≥64 ≥4 ≥16 ≥16 ≥16 ≥32 ≥32c 2 24
PTZ, piperacillin-tazobactam; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; CEP, cefepime; GEM, gentamicin; ANK, amikacin; CIP, ciprofloxacin; COL, colistin; IPM,
imipenem; MEM, meropenem; TYG, tigecycline.
aE-test MIC 36 lg/mL.
bE-test MIC 96 lg/mL.
cE-test MIC 256 lg/mL.
100-bp
deletion
ISKpn7
- tnpA
ISKpn6
816U 3098U KPCfw KPCrv 4714
Tn4401 isoform a  
9,9 Kb
blaKPC-2istA istBtnpAtnpR
FIG. 1. Schematic representation of the genetic structures from Tn4401 isoform a identified in the surroundings of blaKPC-2 gene. Genes and their
corresponding transcription orientations are shown by horizontal arrows. Empty triangles represent inverted repeats (IRs) that flank Tn4401
structure. Internal grey triangles represent IRs from ISKpn6 and ISKpn7. The 100-bp deletion characteristic of Tn4401 isoform a is indicated above
the sequence. Primers used are shown below the sequence: KPCfw, KPCrv [15], 816U, 3098U, 4714 [26].
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the causative agent to our hospital, as may be the case
identified in the root-cause analysis [24].
The KPC-KP isolates exhibited a multiresistant antibiotic
phenotype including resistance to colistin and intermediate
susceptibility to tigecycline. Based on pulsed field gel electro-
phoresis analysis they represent a single clone and they belong
to the internationally distributed ST258 KPC-KP clone,
allowing us to propose their introduction and the occurrence
of cross-transmission between patients. Both clinical cases had
risk factors previously reported to be associated with the
acquisition of KPC-producing bacteria: prolonged ICU stay,
invasive devices, immunosuppression and previous multiple
antibiotic therapies, including ciprofloxacin, tazobactam-piper-
acillin and imipenem [25].
This is the first description of isolates belonging to the
KPC-KP ST258, exhibiting co-resistance to gentamycin, colistin
and tigecycline intermediate susceptibility, acquiring further
amikacin resistance.
The first patient had a KPC-KP asymptomatic cathe-
ter-related bacteriuria, considered the source for the
cross-transmission, and his death was related to Salmonella
sepsis. In contrast, the second patient had multiple sites
colonized, and developed severe sepsis associated with
KPC-KP ventilator-associated pneumonia.
The core measures adopted according to European expert
opinion were reinforced and have been successful in prevent-
ing evolution towards resistance dissemination [8].
The deletions in the upstream genetic environment of the
blaKPC gene increased the level of KPC production, in
accordance with the high-level of carbapenem resistance
observed [26]. Even though B1 and B6 isolates were the same
strain based on pulsed field gel electrophoresis analysis, they
had different behaviours concerning their antibiotic suscepti-
bility and the population analysis profile study. A progressive
increase in the MICS for aminoglycosides and b-lactams, and a
decreased susceptibility to fosfomycin was observed through-
out the administration of combined antimicrobial regimens in
patient B. Even though pre- and post-treatment isolates
possessed ompk36 genes identical to a previously described
functional protein, a decrease in the ompk36 expression level
could not be discounted.
In addition, selection of mutants with resistance to different
antibiotic classes could have emerged by the acquisition of a
resistance mechanism with a broad range specificity spectrum.
Further studies are needed to understand the molecular basis
of these complex and variable resistance phenotypes and to
evaluate their frequency and clinical significance. To counteract
the emergency of carbapenem resistance, new antibiotic
regimens need to be developed and hospital infection control
and diagnostic microbiology practice must be improved.
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